Precision Medicine | The company's focused strategy targeting genetically defined patient populations aligns with industry trends toward personalized cancer therapies, addressing significant unmet needs in specialized oncology segments |
Regulatory Momentum | Discover how Nuvalent's completed rolling NDA submission for ROS1-positive patients and anticipated pivotal data by year-end 2025 create near-term catalysts for potential market authorization |
Analyst Outlook | Price targets range from $116 to $189 with strong buy consensus, reflecting confidence in the therapeutic approach despite projected losses of approximately $5.61-$5.75 per share through fiscal years |
Clinical Excellence | Neladalkib demonstrates exceptional durability of response in ALK-positive non-small cell lung cancer, exceeding initial expectations and positioning as a competitive differentiator in targeted oncology treatments |
Metrics to compare | NUVL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNUVLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.7x | −5.8x | −0.4x | |
PEG Ratio | 0.58 | 0.02 | 0.00 | |
Price / Book | 8.3x | 3.6x | 2.6x | |
Price / LTM Sales | - | 95.0x | 3.0x | |
Upside (Analyst Target) | 0.4% | 101.8% | 56.2% | |
Fair Value Upside | Unlock | −4.7% | 8.9% | Unlock |
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.